Lumosa Therapeutics Co (ROCO:6535) Cyclically Adjusted FCF per Share: NT$-2.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$90.10
GF Value NT$127.52
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Cyclically Adjusted FCF per Share?

Lumosa Therapeutics Co ROCO:6535 +1.58% 70 Cyclically Adjusted FCF per Share is NT$-2.16 as of Mar. 2026. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$127.52 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lumosa Therapeutics Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was NT$-0.312. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-2.16 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-26), Lumosa Therapeutics Co's current stock price is NT$90.10. Lumosa Therapeutics Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was NT$-2.16. Lumosa Therapeutics Co's Cyclically Adjusted Price-to-FCF of today is .


Lumosa Therapeutics Co  (ROCO:6535) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lumosa Therapeutics Co Cyclically Adjusted FCF per Share Related Terms


Lumosa Therapeutics Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co Cyclically Adjusted FCF per Share Chart

Lumosa Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.12 -2.15

Lumosa Therapeutics Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.13 -2.19 -2.15 -2.15 -2.16

ROCO:6535 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Lumosa Therapeutics Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumosa Therapeutics Co Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's Cyclically Adjusted Price-to-FCF falls into.


ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lumosa Therapeutics Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.312/330.2130*330.2130
=-0.312

Current CPI (Mar. 2026) = 330.2130.

Lumosa Therapeutics Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.573 241.018 -0.785
201609 -0.060 241.428 -0.082
201612 -0.595 241.432 -0.814
201703 -0.319 243.801 -0.432
201706 -0.058 244.955 -0.078
201709 -0.271 246.819 -0.363
201712 -0.089 246.524 -0.119
201803 -0.396 249.554 -0.524
201806 -0.242 251.989 -0.317
201809 -0.305 252.439 -0.399
201812 0.027 251.233 0.035
201903 -0.305 254.202 -0.396
201906 -0.453 256.143 -0.584
201909 -0.595 256.759 -0.765
201912 -1.876 256.974 -2.411
202003 1.245 258.115 1.593
202006 -0.789 257.797 -1.011
202009 -0.846 260.280 -1.073
202012 -0.640 260.474 -0.811
202103 -0.608 264.877 -0.758
202106 -0.688 271.696 -0.836
202109 -0.540 274.310 -0.650
202112 -1.150 278.802 -1.362
202203 -0.456 287.504 -0.524
202206 -0.542 296.311 -0.604
202209 -0.603 296.808 -0.671
202212 -0.243 296.797 -0.270
202303 -0.474 301.836 -0.519
202306 -0.680 305.109 -0.736
202309 -0.400 307.789 -0.429
202312 -0.458 306.746 -0.493
202403 -0.491 312.332 -0.519
202406 -0.394 314.175 -0.414
202409 -0.318 315.301 -0.333
202412 -0.602 315.605 -0.630
202503 -0.487 319.799 -0.503
202506 -1.121 322.561 -1.148
202509 -0.309 324.800 -0.314
202512 -0.255 324.054 -0.260
202603 -0.312 330.213 -0.312

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$-2.16 mean?
Lumosa Therapeutics Co (ROCO:6535) has a Cyclically Adjusted FCF per Share of NT$-2.16 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Cyclically Adjusted FCF per Share too high?
Lumosa Therapeutics Co's current Cyclically Adjusted FCF per Share is NT$-2.16. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Lumosa Therapeutics Co's Cyclically Adjusted FCF per Share of NT$-2.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Cyclically Adjusted FCF per Share is NT$-2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$127.52, compared to a current price of NT$90.10 — trading 29.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$-2.16. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Cyclically Adjusted FCF per Share is NT$-2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$90.10 is trading 29.3% below its estimated GF Value™ of NT$127.52. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Cyclically Adjusted FCF per Share: NT$-2.16
  • GF Value™: NT$127.52 vs. price of NT$90.10 (29.3% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$90.10
Price
NT$127.52
GF Value